Evolv Technologies Holdings [EVLV]
The memo issues no verdict. This document states what a position would look like if the book chose to take one, what it would cost, and what could actually be filled. Nothing here is a recommendation to trade.
Spot $5.545 · 2026-07-29
| Alpaca IEX-feed volume, 2026-07-28 | 189,921 shares |
| Feed caveat | Alpaca's IEX feed captures roughly 5% of consolidated volume. True ADV is on the order of 20x the IEX figure — approximately 3.8m shares/day, ~$21m/day at $5.545. This is an estimate from a known scaling factor, not a consolidated-tape measurement. |
| A 1% position in a $50m book | $500k ≈ 90,000 shares ≈ 2.4% of estimated true daily volume |
| Exit at 20% of volume | under one day |
Equity liquidity: PASS. Comfortable at any size this book would take.
January 15, 2027 chain, strikes $3–$12 (Alpaca, 2026-07-29). 24 contracts, total open interest 15,325.
| Type | Strike | OI | Bid × size | Ask × size | IV | Delta |
|---|---|---|---|---|---|---|
| call | 4.00 | 708 | 1.42 × 1540 | 2.52 × 1423 | 0.757 | 0.822 |
| call | 5.00 | 725 | 0.98 × 1194 | 1.57 × 563 | 0.657 | 0.689 |
| call | 5.50 | 373 | 1.07 × 26 | 1.23 × 37 | 0.732 | 0.618 |
| call | 7.00 | 5,471 | 0.57 × 28 | 0.67 × 154 | 0.700 | 0.416 |
| call | 8.00 | 802 | 0.33 × 42 | 0.47 × 301 | 0.685 | 0.304 |
| call | 10.00 | 2,776 | 0.07 × 1949 | 0.23 × 219 | 0.651 | 0.143 |
| put | 5.00 | 966 | 0.63 × 10 | 0.87 × 26 | 0.736 | −0.312 |
| put | 5.50 | 795 | 0.92 × 11 | 1.22 × 33 | 0.773 | −0.378 |
Assessment. Open interest is real (15,325 across the chain; 5,471 on the $7 call alone) and IV at ~70% against 52% realised is expensive but not absurd. The binding constraint is quoted size at the touch, not open interest. The $5.50 call shows 37 up on the offer; the $8.00 call shows 42 on the bid. A $5.50/$8.00 January-2027 call spread at a $0.90 net debit is fillable in roughly 35–40 contracts at the touch — about $3,600 of premium.
That is not a position. It is a rounding error. This is the HCA failure mode exactly: a structure that prices beautifully and cannot be filled.
Conclusion — Liquidity Criteria, options: FAIL for a defined-risk spread at any meaningful size. The only options expression that could absorb real capital is the outright $7.00 January-2027 call (OI 5,471, 154 up on the offer at $0.67 → ~$10,300 at the touch, buildable to perhaps $40–60k of premium over several sessions without moving the market).
If the book wants EVLV exposure, the vehicle is the common stock. Options are available only as a small catalyst overlay, and the memo does not propose one.
Nothing below is a recommendation. It is the arithmetic the book would need.
Common stock. For the reasons above.
| Realised volatility (screen) | 52% |
| Bear case (see Downside Criteria) | −40% |
| Book's standing interim control | inverse-volatility sizing |
| Implied size at a 10%-of-book vol budget vs a 25%-vol reference name | ~0.5x a normal position |
At 52% vol EVLV sizes to roughly half a standard position. A 1% notional position carries the volatility of a 2% position in a 26%-vol name. This is the framework's stated protection against a fat left tail and it does the work here — the bear case is −40% and the position sizes down automatically.
Spot $5.545, at the 3rd percentile of the post-restatement P/S range. There is no valuation reason to wait. There is a process reason: the Q2 2026 print (expected mid-August 2026) is the first data point that will show whether reported growth is in fact stepping down from +45% toward the guided +20–23%. A buyer who wants the recognition question resolved rather than assumed should wait for it.
| Test | Level | Reads as |
|---|---|---|
| ARR growth falls below 15% YoY | ARR < $122m at 9/30/26 | The compounder thesis is broken. Exit. |
| FY2026 revenue guidance cut below $175m | any downward revision | The mix shift was pull-forward and it has exhausted early. Exit. |
| A sixth material weakness, or any new non-reliance | any 8-K Item 4.02 | Exit immediately, no price test. |
| SEC Wells notice | any disclosure | Exit or hedge; the range of outcomes widens beyond what sizing controls. |
| Product gross margin fails to reach +20% by Q4 2026 | quarterly disclosure | The Plexus cost lever has failed; the mix shift is permanently dilutive. Reduce. |
| Price test | −25% from entry ($4.16) with no thesis event | Sizing error, not thesis error. Halve. |
Note the asymmetry deliberately built in: four of the six tests are disclosure tests, not price tests. On a name whose controls management says are not effective, the disclosure is the risk.
Two things, both observable: 1. ICFR effective at 12/31/2026 — i.e. the remaining five material weaknesses remediated. Q1 2026 made zero progress ("no changes"), so this requires visible movement in Q2/Q3. 2. Product gross margin above 20% — evidence the Plexus transition converts the mix shift from dilutive to neutral, at which point reported growth and recurring growth stop diverging in a way that destroys margin.
Not "a 40% grower at 6x sales."
It is: a ~20–21% ARR compounder with $299m of contracted RPO, positive Adjusted EBITDA, $32.4m of net cash and a genuine product cycle (eXpedite), trading at the 3rd percentile of its own post-restatement multiple range because the market is discounting an open SEC enforcement matter and five unremediated material weaknesses.
That is a sentiment mean-reversion trade with a disclosure-risk tail — which the 12-month target quantifies at +26% and the implied-path test says does not clear the five-year ownership standard.
Those are different questions and the memo answers both without reconciling them. Reconciliation is the book's job.